Prognostic Value of Circulating Tumor DNA (ctDNA) in Oncogene-Driven NSCLC: Current Knowledge and Future Perspectives.

Zografos, Eleni; Dimitrakopoulos, Foteinos-Ioannis; Koutras, Angelos

Zografos, Eleni; Dimitrakopoulos, Foteinos-Ioannis; Koutras, Angelos.

Afiliación

Zografos E; Division of Oncology, University Hospital of Patras, University of Patras, 26504 Patras, Greece.
Dimitrakopoulos FI; Molecular Oncology Laboratory, Division of Oncology, Department of Medicine, University of Patras, 26504 Patras, Greece.
Koutras A; Division of Oncology, University Hospital of Patras, University of Patras, 26504 Patras, Greece.

Cancers (Basel) ; 14(19)2022 Oct 10.

Article en En | MEDLINE | ID: mdl-36230877

Palabras clave

NSCLC; ctDNA; driver mutations; liquid biopsy; minimal residual disease (MRD)

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Cancers (Basel) Año: 2022 Tipo del documento: Article País de afiliación: Grecia

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google